Original paper
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Volume: 377, Issue: 19, Pages: 1824 - 1835
Published: Nov 9, 2017
Abstract
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected...
Paper Details
Title
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Published Date
Nov 9, 2017
Volume
377
Issue
19
Pages
1824 - 1835
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History